SCHEMBL22492744

SCHEMBL22492744

CC(C)[Si](C#Cc1cccc(N)c1)(C(C)C)C(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
RET P07949 1/20 0.42
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
PDK1 Q15118 1/20 0.41
ADRB2 P07550 1/20 0.39
RAB9A P51151 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP3A4 P08684 2/20 0.38
CASP1 P29466 1/20 0.38
RECQL P46063 1/20 0.38
FFAR1 O14842 1/20 0.38
HCRTR1 O43613 1/20 0.38
ASIC3 Q9UHC3 2/20 0.36
SLC6A2 P23975 1/20 0.34
GRM5 P41594 1/20 0.34
IKBKB O14920 1/20 0.34
HSD17B2 P37059 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CSNK2A2 P19784 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31236140 1.00 ABL1 (0.42) ABL1RETPIK3CAMTORPDK1
SCHEMBL2418110 0.79 PIK3CA (0.44) ABL1RETPIK3CAMTORPDK1
SCHEMBL20102200 0.79 GRM5 (0.45) ABL1PIK3CACYP3A4FFAR1GRM5
SCHEMBL26988477 0.79 GRM5 (0.44) GRM5ALDH1A1CACNA2D1CACNB2CACNA1C
SCHEMBL27953324 0.77 APP (0.52) PIK3CAMTORPDK1RAB9AL3MBTL1
SCHEMBL31387703 0.77 APP (0.48) MTORRAB9ACYP3A4FFAR1GRM5
SCHEMBL4968126 0.76 CYP3A4 (0.58) ABL1RETPIK3CAMTORPDK1
SCHEMBL30426677 0.76 CYP3A4 (0.42) ABL1RETPIK3CAMTORPDK1
SCHEMBL29433431 0.74 CYP3A4 (0.50) ABL1RETPIK3CAMTORPDK1
SCHEMBL1507506 0.74 CYP3A4 (0.50) ABL1RETPIK3CAMTORPDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4367103-B1 INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-09-03 EP disclosed
EP-4367103-A1 INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2024-05-15 EP disclosed
WO-2023280970-A1 INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-01-12 WO disclosed
WO-2023280970-A1 INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-01-12 WO disclosed
US-20210188763-A1 COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION UNIV CALIFORNIA (US) 2021-06-24 US disclosed
EP-3717450-A1 COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION The Regents of the University of California (US) 2020-10-07 EP disclosed
CN-105246884-B Urea derivative as kinase inhibitor 瑞斯比维特有限公司 2018-05-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188763-A1 COMPOUNDS AND METHODS FOR HEMATOPOIETIC REGENERATION HGF, CXCL12, CCL11 ABL1 119/4885RET 3152/4885PIK3CA 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.